Nluc Reporter Cell Line - RBE

RBE is an adherent human intrahepatic cholangiocarcinoma cell line established from the liver tumor of a 64-year-old Japanese female patient. It was derived from the adenocarcinoma component of a cholangiocarcinoma containing both adenocarcinomatous and sarcomatous regions. Molecular profiling of RBE cells has identified alterations including IDH1 p.R132S and KRAS p.G12V, making the parental line relevant to studies of genetically defined biliary tract cancer. Nluc Reporter Cell Line - RBE is an engineered derivative expressing NanoLuc luciferase. NanoLuc is a compact 19.1 kDa reporter enzyme that produces bright, ATP-independent luminescence in the presence of a compatible furimazine-based substrate. Its strong signal and low background allow sensitive detection and quantitative measurement of reporter-expressing RBE cells.

This reporter line can support investigations of cholangiocarcinoma proliferation, survival, metabolism, migration, invasion, and treatment response. NanoLuc activity offers a convenient readout for multiwell screening of chemotherapeutic compounds, kinase inhibitors, IDH-directed agents, biologics, and combination regimens. The model may also help examine signaling dependencies associated with IDH1 or KRAS alterations and evaluate mechanisms underlying therapeutic sensitivity or resistance. In spheroids and other three-dimensional cultures, bioluminescence can provide a practical measure of viable cell burden when direct counting is difficult. In appropriately validated xenograft or orthotopic models, NanoLuc-based imaging may enable longitudinal monitoring of tumor establishment, intrahepatic growth, dissemination, and treatment response.